Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
See Detailed Description
This is a randomised, double-blind, placebo-controlled, multicentre, global Phase III trial
comparing the efficacy of adjuvant oral lapatinib versus placebo in high-risk subjects with
head and neck cancer following surgery. Lapatinib or placebo will be administered
post-operatively in combination with chemoradiotherapy followed by maintenance with
lapatinib or placebo for 1 year. The primary goal is to determine if lapatinib is effective
at reducing the recurrence of the disease in these high-risk patients.
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of
Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by
Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous
Cell Carcinoma of the Head and Neck (SCCHN)
We found this trial at
4
sites
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1 Medical Center Drive
Morgantown, West Virginia 26506
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
Click here to add this to my saved trials